Charles D. Bengtson

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Hyperglycaemia in cystic fibrosis adversely affects BK channel function critical for mucus clearance”.

Hyperglycaemia in cystic fibrosis adversely affects BK channel function critical for mucus clearance

European Respiratory Journal(2020)10.1183/13993003.00509-2020

N/A

0DataRank · unranked

21 citations

Michael D. Kim, Abeer Anabtawi, Jianghua He, John S. Dennis, Sara B. Miller +4 more

An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19

Frontiers in Medicine(2021)10.3389/fmed.2021.630209

N/A

0DataRank · unranked

23 citations

Robert N. Montgomery, Usman Nazir, Lewis Satterwhite, Michael D. Kim, Nathan C. Bahr +4 more

The CFTR Amplifier Nesolicaftor Rescues TGF-β1 Inhibition of Modulator-Corrected F508del CFTR Function

International Journal of Molecular Sciences(2022)10.3390/ijms231810956

N/A

0DataRank · unranked

17 citations

Neerupma Silswal, Nathalie Baumlin, Makoto Yoshida, John S. Dennis, Sireesha Yerrathota +3 more

Losartan in hospitalized patients with COVID-19 in North America: An individual participant data meta-analysis

Medicine(2023)10.1097/md.0000000000033904

N/A

0DataRank · unranked

3 citations

Malathi Ram, Daniel O. Scharfstein, Tianjing Li, P Khanal, Sheriza Baksh +13 more

Neutrophil store-operated Ca2+ entry: A correctable biomarker of cystic fibrosis lung disease progression

Journal of Cystic Fibrosis(2025)10.1016/j.jcf.2025.08.014

N/A

0DataRank · unranked

2 citations

Matthew Biggart, Charles D. Bengtson, Maria F. Sassano, Robert Tarran, Joe A. Wrennall